Embed
Email

Ch 2036 20Dysrhythmias

Document Sample
Ch 2036 20Dysrhythmias
Shared by: HC11111011432
Categories
Tags
Stats
views:
4
posted:
11/10/2011
language:
English
pages:
144
Focus on

Dysrhythmias

(Relates to Chapter 36,

“Nursing Management: Dysrhythmias,”

in the textbook)





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Dysrhythmias

 Abnormal cardiac rhythms are

termed dysrhythmias

 Prompt assessment of

dysrhythmias and the patient’s

response to the rhythm is

critical





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Properties of Cardiac Cells

 Automaticity – certain cardiac cells can

discharge spontaneously



 Excitability – property of myocardial tissue

that allows it to be depolarized by a stimulus



 Conductivity – ability to transmit an impulse

along a membrane in an orderly manner



 Contractility – ability to respond

mechanically to an impulse

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Phases of Cardiac Action

Potential









Fig. 36-1

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Nervous System Control of

the Heart



 Autonomic nervous system

controls:

 Rate of impulse formation

 Speed of conduction

 Strength of contraction









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Nervous System Control of

the Heart

 Parasympathetic nervous system:

Vagus nerve

 Decreases rate

 Slows impulse conduction

 Decreases force of contraction

 Sympathetic nervous system

 Increases rate

 Increases force of contraction

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

12-Lead ECG

 12 recording leads

 Six leads measure electrical forces

in the frontal plane (leads I, II, III,

aVR, aVL, and aVF)

 Six leads (V1–V6) measure the

electrical forces in the horizontal

plane (precordial leads)



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Lead Placement









Fig. 36-2









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

12-Lead ECG









Fig. 36-3







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Tips for applying electrodes

 Make sure skin is thoroughly dry.

 Clip chest hair.

 Remove any excess skin oil with alcohol.

 Apply tincture of benzoin if keeping electrodes is difficult.

 Connect each lead wire to a disc before applying it to the chest.

 Make sure the center of the electrode disc is moist.

 Avoid applying electrodes over these areas:

 Bony areas skin folds

 Scar tissue breast tissue

 Muscle mass (significant) heart apex









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Assessment of Cardiac Rhythm









Fig. 36-5







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

EKG Paper









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Assessment of Cardiac Rhythm









Fig. 36-6









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Assessment of Cardiac Rhythm









Fig. 36-9



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Normal Sinus Rhythm



 Sinus node fires 60 to 100 bpm

 Follows normal conduction

pattern







Fig. 36-8







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Evaluation of Dysrhythmias



 Holter monitoring

 Event recorder monitoring

 Exercise treadmill testing

 Signal-averaged ECG

 Electrophysiologic study







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Sinus Bradycardia

 Sinus node fires 100 bpm









Fig. 35-11 B



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Sinus Tachycardia

 Clinical associations

 Associated with physiologic stressors

 Exercise

 Pain

 Hypovolemia

 Myocardial ischemia

 Heart failure (HF)

 Fever



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Sinus Tachycardia

 Clinical significance

 Dizziness and hypotension due

to decreased CO

 Increased myocardial oxygen

consumption may lead to angina









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Sinus Tachycardia

 Treatment

 Determined by underlying cause

 -Adrenergic blockers to reduce

HR and myocardial oxygen

consumption

 Antipyretics to treat fever

 Analgesics to treat pain





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Atrial Contraction

 Contraction originating from

ectopic focus in atrium in

location other than SA node

 Travels across atria by abnormal

pathway, creating distorted P

wave

 May be stopped, delayed, or

conducted normally at the AV

node

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Atrial Contraction









Fig. 36-12









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Atrial Contraction

 Clinical associations

 Can result from

 Emotional stress

 Use of caffeine, tobacco, alcohol

 Hypoxia

 Electrolyte imbalances

 COPD

 Valvular disease



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Atrial Contraction

 Clinical significance

 Isolated PACs are not significant in

those with healthy hearts

 In persons with heart disease, may

be warning of more serious

dysrhythmia







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Atrial Contraction

 Treatment

 Depends on symptoms

 -Adrenergic blockers may be

used to decrease PACs

 Reduce or eliminate caffeine









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)



 Originates in ectopic focus

anywhere above bifurcation of

bundle of His

 Run of repeated premature beats

is initiated and is usually a PAC

 Paroxysmal refers to an abrupt

onset and termination

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)

 Some degree of AV block may be

present

 Can occur in presence of Wolff-

Parkinson-White (WPW)

syndrome







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)









Fig. 36-13









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)

 Clinical associations

 In a normal heart

 Overexertion

 Emotional stress

 Stimulants

 Digitalis toxicity

 Rheumatic heart disease

 CAD

 Cor pulmonale

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)

 Clinical significance

 Prolonged episode and HR >180

bpm may precipitate ↓ CO

 Palpitations

 Hypotension

 Dyspnea

 Angina





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)

 Treatment

 Vagal maneuvers: Valsalva, coughing

 IV adenosine

 If vagal maneuvers and/or drug

therapy is ineffective and/or patient

becomes hemodynamically unstable,

DC cardioversion should be used



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Paroxysmal Supraventricular

Tachycardia (PSVT)

 Treatment

 If PSVT recurs in patients with

WPW, they may ultimately be

treated with radiofrequency

catheter ablation of the accessory

pathway





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Flutter

 Atrial tachydysrhythmia

identified by recurring, regular,

sawtooth-shaped flutter waves

 Originates from a single ectopic

focus







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Flutter









Fig. 36-14A









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Flutter

 Clinical associations

 Usually occurs with

 CAD

 Hypertension

 Mitral valve disorders

 Pulmonary embolus

 Chronic lung disease

 Cardiomyopathy

 Hyperthyroidism

 Drugs: Digoxin, quinidine, epinephrine

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Flutter

 Clinical significance

 High ventricular rates (>100) and

loss of the atrial ―kick‖ can decrease

CO and precipitate HF, angina

 Risk for stroke due to risk of

thrombus formation in the atria







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Flutter

 Treatment

 Primary goal is to slow ventricular

response by increasing AV block

 Drugs to slow HR: Calcium channel

blockers, -adrenergic blockers

 Electrical cardioversion may be used

to convert the atrial flutter to sinus

rhythm emergently and electively



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Flutter

 Treatment

 Primary goal is to slow ventricular

response by increasing AV block

 Antidysrhythmia drugs to convert

atrial flutter to sinus rhythm or to

maintain sinus rhythm (e.g.,

amiodarone, propafenone)

 Radiofrequency catheter ablation can

be curative therapy for atrial flutter



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Total disorganization of atrial

electrical activity due to multiple

ectopic foci resulting in loss of

effective atrial contraction

 Most common dysrhythmia

 Prevalence increases with age







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

QuickTime™ and a

YUV420 codec decompressor

are needed to see this picture.









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation









Fig. 36-14B









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Clinical associations

 Usually occurs with

 Underlying heart disease, such as

rheumatic heart disease, CAD

 Cardiomyopathy

 HF

 Pericarditis





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Clinical associations

 Often acutely caused by

 Thyrotoxicosis

 Alcohol intoxication

 Caffeine use

 Electrolyte disturbance

 Cardiac surgery





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Clinical significance

 Can result in decrease in CO due to

ineffective atrial contractions (loss

of atrial kick) and rapid ventricular

response

 Thrombi may form in the atria as a

result of blood stasis

 Embolus may develop and travel to

the brain, causing a stroke

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Treatment

 Goals

 Decrease ventricular response

 Prevent embolic stroke

 Drugs for rate control: digoxin, -

adrenergic blockers, calcium

channel blockers

 Long-tern anticoagulation:

Coumadin

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Treatment

 For some patients, conversion to

sinus rhythm may be considered

 Antidysrhythmic drugs used for

conversion: Amiodarone,

propafenone

 DC cardioversion may be used to

convert atrial fibrillation to

normal sinus rhythm

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Treatment

 If patient has been in atrial

fibrillation for >48 hours,

anticoagulation therapy with

warfarin is recommended for

3 to 4 weeks before cardioversion

and for 4 to 6 weeks after

successful cardioversion



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Atrial Fibrillation

 Treatment

 Radiofrequency catheter ablation

 Maze procedure

 Modifications to the Maze

procedure

 Use of cold (cryoablation)

 Use of heat (high-intensity

ultrasound)

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Junctional Dysrhythmias



 Dysrhythmia that originates in

area of AV node

 SA node has failed to fire or

impulse has been blocked at the

AV node







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Junctional Dysrhythmias









Fig. 36-15

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Junctional Dysrhythmias

 Clinical associations

 CAD

 HF

 Cardiomyopathy

 Electrolyte imbalances

 Inferior MI

 Rheumatic heart disease

 Drugs: Digoxin, amphetamines,

caffeine, nicotine

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Junctional Dysrhythmia

 Clinical significance

 Serves as safety mechanism

when SA node has not been

effective

 Escape rhythms should not be

suppressed

 If rhythms are rapid, may result

in reduction of CO and HF

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Junctional Dysrhythmias

 Treatment

 If symptomatic, atropine

 Accelerated junctional rhythm and

junctional tachycardia caused by

digoxin toxicity, digoxin is held

 -Adrenergic blockers, calcium channel

blockers, and amiodarone used for rate

control for junctional tachycardia not

caused by digoxin toxicity

 DC cardioversion is contraindicated

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

First-Degree AV Block

 Every impulse is conducted to the

ventricles, but duration of AV

conduction is prolonged









Fig. 36-16A







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

First-Degree AV Block

 Clinical associations

 Usually occurs with

 MI

 CAD

 Rheumatic fever

 Hyperthyroidism

 Vagal stimulation

 Drugs: Digoxin, -adrenergic blockers,

calcium channel blockers, flecainide

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

First-Degree AV Block



 Clinical significance

 Usually asymptomatic

 May be a precursor to higher

degrees of AV block

 Treatment

 Check medications

 Continue to monitor



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 1 (Mobitz I, Wenckebach)

 Gradual lengthening of the PR

interval, due to prolonged AV

conduction time

 Atrial impulse is nonconducted and

a QRS complex is blocked (missing)

 Usually block occurs at AV node,

but can occur in His-Purkinje

system



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 1 (Mobitz I, Wenckebach)









Fig. 36-16B







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 1 (Mobitz I, Wenckebach)

 Clinical associations

 Drugs: digoxin, -adrenergic

blockers

 May be associated with CAD and

other diseases that can slow AV

conduction







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 1 (Mobitz I, Wenckebach)



 Clinical significance

 Usually a result of myocardial

ischemia or infarction

 Almost always transient and well

tolerated

 May be a warning signal of a more

serious AV conduction disturbance



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 1 (Mobitz I, Wenckebach)



 Treatment

 If symptomatic, atropine or a

temporary pacemaker

 If asymptomatic, monitor with a

transcutaneous pacemaker on

standby

 Symptomatic bradycardia is more

likely with one or more of the

following: hypotension, HF, shock

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 2 (Mobitz II)

P wave is nonconducted

without progressive antecedent

PR lengthening

 Usually occurs when a block in

one of the bundle branches is

present





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 2 (Mobitz II)









Fig. 36-16C







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 2 (Mobitz II)



 Clinical associations

 Rheumatic heart disease

 CAD

 Anterior MI

 Digitalis toxicity





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 2 (Mobitz II)

 Clinical significance

 Often progresses to third-degree

AV block and is associated with a

poor prognosis

 Reduced HR often results in

decreased CO with subsequent

hypotension and myocardial

ischemia



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Second-Degree AV Block,

Type 2 (Mobitz II)

 Treatment

 If symptomatic (e.g., hypotension,

angina) before permanent

pacemaker can be inserted,

temporary transvenous or

transcutaneous pacemaker

 Permanent pacemaker





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Third-Degree AV Heart Block

(Complete Heart Block)

 Form of AV dissociation in which

no impulses from the atria are

conducted to the ventricles

 Atria are stimulated and contract

independently of the ventricles

 Ventricular rhythm is an escape

rhythm

 Ectopic pacemaker may be above

or below the bifurcation of the

bundle of His

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Third-Degree AV Heart Block

(Complete Heart Block)









Fig. 36-16 D

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Third-Degree AV Heart Block

(Complete Heart Block)

 Clinical associations

 Severe heart disease: CAD, MI,

myocarditis, cardiomyopathy

 Systemic diseases: Amyloidosis,

scleroderma

 Drugs: Digoxin, -adrenergic

blockers, calcium channel blockers



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Third-Degree AV Heart Block

(Complete Heart Block)

 Clinical significance

 Decreased CO with subsequent

ischemia, HF, and shock

 Syncope may result from severe

bradycardia or even periods of

asystole







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Third-Degree AV Heart Block

(Complete Heart Block)

 Treatment

 If symptomatic, transcutaneous

pacemaker until a temporary

transvenous pacemaker can be

inserted

 Drugs (e.g., atropine, epinephrine):

Temporary measure to increase HR

and support BP until temporary

pacing is initiated

 Permanent pacemaker as soon as

possible

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Ventricular

Contractions

 Contraction originating in

ectopic focus of the ventricles

 Premature occurrence of a wide

and distorted QRS complex

 Multifocal, unifocal, ventricular

bigeminy, ventricular trigeminy,

couples, triplets, R on T

phenomena

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Ventricular

Contractions









Fig. 36-17





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Ventricular

Contractions

 Clinical associations

 Stimulants: Caffeine, alcohol, nicotine,

aminophylline, epinephrine, isoproterenol

 Digoxin

 Electrolyte imbalances

 Hypoxia

 Fever

 Disease states: MI, mitral valve prolapse,

HF, CAD



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Ventricular

Contractions

 Clinical significance

 In normal heart, usually benign

 In heart disease, PVCs may decrease CO

and precipitate angina and HF

 Patient’s response to PVCs must be

monitored

 PVCs often do not generate a sufficient

ventricular contraction to result in a

peripheral pulse

 Apical-radial pulse rate should be

assessed to determine if pulse deficit

exists

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Ventricular

Contractions

 Clinical significance

 Represents ventricular irritability

 May occur

 After lysis of a coronary artery

clot with thrombolytic therapy in

acute MI—reperfusion

dysrhythmias

 Following plaque reduction after

percutaneous coronary

intervention

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Premature Ventricular

Contractions

 Treatment

 Based on cause of PVCs

 Oxygen therapy for hypoxia

 Electrolyte replacement

 Drugs: -Adrenergic blockers,

procainamide, amiodarone,

lidocaine



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Run of three or more PVCs

 Monomorphic, polymorphic,

sustained, and nonsustained

 Considered life-threatening

because of decreased CO and the

possibility of deterioration

ventricular fibrillation



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia









Fig. 36-18A

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia









Fig. 36-18B









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Clinical associations

 MI

 CAD

 Electrolyte imbalances

 Cardiomyopathy

 Mitral valve prolapse

 Long QT syndrome

 Digitalis toxicity

 Central nervous system disorders

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Clinical significance

 VT can be stable (patient has a pulse)

or unstable (patient is pulseless)

 Sustained VT: Severe decrease

in CO

–Hypotension

–Pulmonary edema

–Decreased cerebral blood flow

–Cardiopulmonary arrest

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Clinical significance

 Treatment for VT must be rapid

 May recur if prophylactic

treatment is not initiated

 Ventricular fibrillation may

develop







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Treatment

 Precipitating causes must be identified

and treated (e.g., hypoxia)

 Monomorphic VT

 Hemodynamically stable

(e.g., + pulse) + preserved LV

function: IV procainamide, sotalol,

amiodarone, or lidocaine

 Hemodynamically unstable or poor

LV function: IV amiodarone or

lidocaine followed by cardioversion

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Treatment

 Polymorphic VT with a normal

baseline QT interval: -

Adrenergic blockers, lidocaine,

amiodarone, procainamide, or

sotalol

 Cardioversion is used if drug

therapy is ineffective



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Treatment

 Polymorphic VT with a prolonged

baseline QT interval: IV

magnesium, isoproterenol,

phenytoin, lidocaine, or

antitachycardia pacing

 Drugs that prolong the QT interval

should be discontinued

 If the rhythm is not converted,

cardioversion may be needed

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Tachycardia

 Treatment

 VT without a pulse is a life-

threatening situation

 Cardiopulmonary

resuscitation (CPR) and rapid

defibrillation

–Epinephrine if defibrillation

is unsuccessful



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Fibrillation

 Severe derangement of the

heart rhythm characterized on

ECG by irregular undulations

of varying contour and

amplitude

 No effective contraction or CO

occurs



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Fibrillation









Fig. 36-19

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Fibrillation

 Clinical associations

 Acute MI, CAD, cardiomyopathy

 VF may occur during cardiac pacing

or cardiac catheterization

 VF may occur with coronary

reperfusion after fibrinolytic therapy

 Accidental electrical shock

 Hyperkalemia

 Hypoxia

 Acidosis

 Drug toxicity

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Fibrillation

 Clinical significance

 Unresponsive, pulseless, and

apneic state

 If not treated rapidly, death

will result









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Ventricular Fibrillation

 Treatment

 Immediate initiation of CPR

and advanced cardiac life

support (ACLS) measures with

the use of defibrillation and

definitive drug therapy







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Asystole

 Represents total absence of

ventricular electrical activity

 No ventricular contraction

(CO) occurs because

depolarization does not occur







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Asystole

 Clinical associations

 Advanced cardiac disease

 Severe cardiac conduction

system disturbance

 End-stage HF









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Asystole

 Clinical significance

 Unresponsive, pulseless, and

apneic state

 Prognosis for asystole is

extremely poor









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Asystole

 Treatment

 CPR with initiation of ACLS

measures (e.g., intubation,

transcutaneous pacing, and IV

therapy with epinephrine and

atropine)







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pulseless Electrical Activity

 Electricalactivity can be

observed on the ECG, but

there is no mechanical activity

of the ventricles and the

patient has no pulse









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pulseless Electrical Activity

 Clinical associations

 Hypovolemia  Drug overdose

 Hypoxia  Cardiac

tamponade

 Metabolic acidosis  MI

 Hyperkalemia or  Tension

hypokalemia pneumothorax

 Hypothermia  Pulmonary

embolus



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pulseless Electrical Activity

 Treatment

 CPR followed by intubation and

IV epinephrine

 Atropine is used if the ventricular

rate is slow

 Treatment is directed toward

correction of the underlying cause





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Sudden Cardiac Death (SCD)

 Death from a cardiac cause

 Majority of SCDs result from

ventricular dysrhythmias

 Ventricular tachycardia

 Ventricular fibrillation







Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Prodysrhythmia

 Clinical significance

 Antidysrhythmic drugs may cause

life-threatening dysrhythmias

 Risk increases in presence of

 Severe LV dysfunction

 Digoxin and class IA, IC, and III

antidysrhythmia drugs





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Prodysrhythmia

 Treatment

 First several days of drug

therapy are the vulnerable period

for developing prodysrhythmias

 Many oral antidysrhythmia drug

regimens are initiated in a

monitored hospital setting



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Defibrillation

 Most effective method of

terminating VF and pulseless

VT

 Passage of DC electrical shock

through the heart to depolarize

the cells of the myocardium to

allow the SA node to resume

the role of pacemaker

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Defibrillation

 Deliver

energy using a

monophasic or biphasic

waveform

 Monophasic defibrillators deliver

energy in one direction

 Biphasic defibrillators deliver

energy in two directions

 Deliver successful shocks at

lower energies and with fewer

postshock ECG abnormalities

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Defibrillation









Fig. 36-20 A and B



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Defibrillation

 Output is measured in joules or

watts per second

 Recommended energy for initial

shocks in defibrillation

 Biphasic defibrillators: First and

successive shocks: 150 to 200 joules

 Monophasic defibrillators: Initial

shock at 360 joules

 After the initial shock, chest

compressions (CPR) should be

started

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Defibrillation









Fig. 36-21





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Synchronized Cardioversion

 Choice of therapy for

hemodynamically unstable

ventricular or supraventricular

tachydysrhythmias

 Synchronized circuit delivers a

countershock on the R wave of

the QRS complex of the ECG

 Synchronizer switch must be

turned

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Implantable Cardioverter-

Defibrillator (ICD)

 Appropriate for patients who

 Have survived SCD

 Have spontaneous sustained VT

 Have syncope with inducible

ventricular tachycardia/fibrillation

during EPS

 Are at high risk for future life-

threatening dysrhythmias



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Implantable Cardioverter-

Defibrillator (ICD)

 Consists of a lead system placed via

subclavian vein to the endocardium

 Battery-powered pulse generator is

implanted subcutaneously

 ICD sensing system monitors the HR

and rhythm and identifies VT or VF

 Approximately 25 seconds after

detecting VT or VF, ICD delivers <25

joules

 If first shock is unsuccessful, ICD

recycles and delivers successive shocks

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Implantable Cardioverter-

Defibrillator (ICD)

 ICDs are equipped with

antitachycardia and

antibradycardia pacemakers

 Initiates overdrive pacing of

supraventricular and ventricular

tachycardias

 Provides backup pacing for

bradydysrhythmias that may occur

after defibrillation discharges

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Implantable Cardioverter-

Defibrillator (ICD)









Fig. 36-22

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Implantable Cardioverter-

Defibrillator (ICD)

 Education is extremely important

 Variety of emotions are possible

 Fear of body image change

 Fear of recurrent dysrhythmias

 Expectation of pain with ICD

discharge

 Anxiety about going home

 Participation in an ICD support

group should be encouraged

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers

 Used to pace the heart when the normal

conduction pathway is damaged or diseased

 Pacing circuit consists of a power source,

one or more conducting (pacing) leads,

and the myocardium

 Electrical signal (stimulus) travels from

the pacemaker, through the leads, to the

wall of the myocardium

 Myocardium is ―captured‖ and stimulated

to contract

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers









Fig. 36-23





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers

 Initially indicated for symptomatic

bradydysrhythmias

 Antitachycardia and overdrive pacing

 Antitachycardia pacing: Delivery of

a stimulus to the ventricle to

terminate tachydysrhythmias

 Overdrive pacing: Pacing the atrium

at rates of 200 to 500 impulses per

minute to terminate atrial

tachycardias

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers

 Temporary pacemaker: Power

source outside the body

 Transvenous

 Epicardial

 Transcutaneous









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers









Fig. 36-25 Fig. 36-26





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers









Fig. 36-27





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers

 Permanent pacemaker: Implanted

totally within the body

 Cardiac resynchronization therapy

(CRT): Pacing technique that

resynchronizes the cardiac cycle by

pacing both ventricles

 Combined CRT with an ICD for

maximum therapy

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers









Fig. 36-24 A





Fig. 36-24 B



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers

 Pacemaker malfunction

 Failure to sense: Failure to recognize

spontaneous atrial or ventricular

activity and pacemaker fires

inappropriately

 Lead damage, battery failure,

dislodgement of the electrode





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacemakers

 Pacemaker malfunction

 Failure to capture: Electrical charge

to myocardium is insufficient to

produce atrial or ventricular

contraction

 Lead damage, battery failure,

dislodgement of the electrode,

fibrosis at the electrode tip

 Patient education

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Catheter Ablation Therapy

 Electrode-tipped ablation catheter

―burns‖ accessory pathways or

ectopic sites in the atria, AV node,

and ventricles

 Nonpharmacologic treatment for

 AV nodal reentrant tachycardia

 Reentrant tachycardia related

to accessory bypass tracts

 Control of ventricular response

of certain tachydysrhythmias

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Catheter Ablation Therapy

 Complete ablation of the AV

node or bundle of His may be

performed in some cases of

uncontrolled ventricular

response in atrial fibrillation or

flutter unresponsive to medical

therapy

 Permanent pacemaker required



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Pacer spikes









Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

ECG Changes Associated with

Acute Coronary Syndrome (ACS)









Fig. 36-29 B





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

ECG Changes Associated with

Acute Coronary Syndrome (ACS)









Fig. 36-29 C





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Syncope

 Brief lapse in consciousness

accompanied by a loss in postural

tone (fainting)

 Cardiovascular causes

 Neurocardiogenic syncope or

―vasovagal‖ syncope (e.g., carotid

sinus sensitivity)

 Primary cardiac dysrhythmias

(e.g., tachycardias, bradycardias)



Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Syncope

 Noncardiovascular causes

 Hypoglycemia

 Hysteria

 Unwitnessed seizure

 Vertebrobasilar transient

ischemic attack





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Syncope

 Diagnostic studies

 Echocardiography

 EPS

 Head-upright tilt table testing

 Holter monitor

 Subcutaneously implanted loop

recording device

 1-year mortality rate as high as 30%

for syncope from cardiovascular

cause

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

―How will I know what to do?‖ you ask









 Treat the patient, not the rhythm - is a good place to start

 Anticipate the problem

 Know your drugs

 Know CPR





Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.


Related docs
Other docs by HC11111011432
BD 20Usme
Views: 5  |  Downloads: 0
10681 r body
Views: 1  |  Downloads: 0
PCI_Study_Guide
Views: 0  |  Downloads: 0
Telefonski_Imenik
Views: 205  |  Downloads: 0
Francis 20GearyLANt018 20trans 20V2
Views: 0  |  Downloads: 0
OBS 20Study 20Guide 204
Views: 1  |  Downloads: 0
EDPWEBPAGE_RELACION 20DE 20DOCENTES 20APROBADOS
Views: 854  |  Downloads: 0
asluniversityworkbook
Views: 1  |  Downloads: 0
chemotherapy
Views: 11  |  Downloads: 0
Killing 20Pablo
Views: 2  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!